ABEO
Abeona Therapeutics Inc.
NASDAQ · USHealthcareBiotechnology
$6.48-7.43%
Price as of Jul 20, 2026
ABEO growth
Abeona Therapeutics Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- +298.8%
- EBIT
- -33.3%
- EPS
- +241.2%
- Free cash flow
- -35.3%
- Operating cash flow
- -29.8%
Forward estimates
- Revenue
- +871.2%
- EBITDA
- —
- EPS
- -81.8%
Three-year CAGR
- Revenue
- +60.3%
- EBITDA
- +238.8%
- EBIT
- -39.3%
- Net income
- +211.7%
- EPS
- +186.5%
- Free cash flow
- -44.2%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.